- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 15 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
- 5 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.3: 4 residues within 4Å:- Chain C: N.1082, T.1084, H.1085, F.1087
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.4: 1 residues within 4Å:- Chain C: N.1118
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.9: 4 residues within 4Å:- Chain D: N.1082, T.1084, H.1085, F.1087
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.10: 1 residues within 4Å:- Chain D: N.1118
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.18: 4 residues within 4Å:- Chain E: N.1082, T.1084, H.1085, F.1087
No protein-ligand interaction detected (PLIP)- 30 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.21: 2 residues within 4Å:- Chain C: Y.1139, N.1142
Ligand excluded by PLIPNAG.22: 4 residues within 4Å:- Chain C: C.2, N.4, C.121, N.122
Ligand excluded by PLIPNAG.23: 2 residues within 4Å:- Chain C: Y.15, N.48
Ligand excluded by PLIPNAG.24: 1 residues within 4Å:- Chain C: N.587
Ligand excluded by PLIPNAG.25: 1 residues within 4Å:- Chain C: N.641
Ligand excluded by PLIPNAG.26: 2 residues within 4Å:- Chain C: N.600, Q.628
Ligand excluded by PLIPNAG.27: 2 residues within 4Å:- Chain C: N.693
- Chain E: Y.780
Ligand excluded by PLIPNAG.28: 3 residues within 4Å:- Chain C: N.107, V.112, F.139
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain C: N.130, N.131, K.132
Ligand excluded by PLIPNAG.30: 2 residues within 4Å:- Chain C: N.315, Q.564
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain C: N.264, N.266
- Chain D: K.542
Ligand excluded by PLIPNAG.32: 4 residues within 4Å:- Chain D: Y.1139, N.1142
- Chain E: K.1141, T.1144
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain D: A.108, T.109, N.110
Ligand excluded by PLIPNAG.34: 5 residues within 4Å:- Chain D: C.2, V.3, N.4, C.121, D.123
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain D: Y.15, N.48
Ligand excluded by PLIPNAG.36: 1 residues within 4Å:- Chain D: N.587
Ligand excluded by PLIPNAG.37: 1 residues within 4Å:- Chain D: N.641
Ligand excluded by PLIPNAG.38: 2 residues within 4Å:- Chain C: Y.780
- Chain D: N.693
Ligand excluded by PLIPNAG.39: 2 residues within 4Å:- Chain D: N.130, N.131
Ligand excluded by PLIPNAG.40: 1 residues within 4Å:- Chain D: N.147
Ligand excluded by PLIPNAG.41: 1 residues within 4Å:- Chain D: N.600
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain C: T.1144
- Chain E: Y.1139, N.1142
Ligand excluded by PLIPNAG.43: 2 residues within 4Å:- Chain E: C.2, N.4
Ligand excluded by PLIPNAG.44: 2 residues within 4Å:- Chain E: Y.15, N.48
Ligand excluded by PLIPNAG.45: 1 residues within 4Å:- Chain E: N.587
Ligand excluded by PLIPNAG.46: 1 residues within 4Å:- Chain E: N.641
Ligand excluded by PLIPNAG.47: 2 residues within 4Å:- Chain D: Y.780
- Chain E: N.693
Ligand excluded by PLIPNAG.48: 2 residues within 4Å:- Chain E: N.131, K.132
Ligand excluded by PLIPNAG.49: 2 residues within 4Å:- Chain E: N.264, N.266
Ligand excluded by PLIPNAG.50: 1 residues within 4Å:- Chain E: N.600
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Wang, L. et al., Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants, including Omicron sublineages. Cell Res. (2022)
- Release Date
- 2022-12-14
- Peptides
- Heavy chain of XGv051: AFH
Light chain of XGv051: BGI
Spike glycoprotein: CDE - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
HF
GH
IB
LG
JI
KC
BD
CE
D
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 15 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
- 5 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 30 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Wang, L. et al., Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants, including Omicron sublineages. Cell Res. (2022)
- Release Date
- 2022-12-14
- Peptides
- Heavy chain of XGv051: AFH
Light chain of XGv051: BGI
Spike glycoprotein: CDE - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
HF
GH
IB
LG
JI
KC
BD
CE
D